JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Cerrado

SectorSanidad

16.76 0.96

Resumen

Variación precio

24h

Actual

Mínimo

16.4

Máximo

16.95

Métricas clave

By Trading Economics

Ventas

132M

160M

Empleados

627

EBITDA

126M

4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+79.11% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

882M

1.9B

Apertura anterior

15.8

Cierre anterior

16.76

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Arcus Biosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 oct 2025, 20:49 UTC

Ganancias

Correction to Thermo Fisher Article on Oct. 22

23 oct 2025, 23:51 UTC

Charlas de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct 2025, 23:37 UTC

Charlas de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct 2025, 22:58 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

23 oct 2025, 22:57 UTC

Charlas de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -2-

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct 2025, 22:17 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct 2025, 21:41 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct 2025, 21:05 UTC

Ganancias

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 oct 2025, 20:35 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct 2025, 20:28 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct 2025, 20:15 UTC

Charlas de Mercado
Ganancias

Global Commodities Roundup: Market Talk

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Adj EPS $1.71

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Sales $5.52B

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q EPS $1.67

23 oct 2025, 20:09 UTC

Ganancias

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct 2025, 20:07 UTC

Ganancias

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct 2025, 20:05 UTC

Ganancias

Intel 3Q Gross Margin 38.2% >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct 2025, 20:04 UTC

Ganancias

Intel: 4Q Guidance Excludes Altera >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Sees 4Q Adj EPS 8c >INTC

Comparación entre iguales

Cambio de precio

Arcus Biosciences Inc previsión

Precio Objetivo

By TipRanks

79.11% repunte

Estimación a 12 Meses

Media 32.33 USD  79.11%

Máximo 54 USD

Mínimo 14 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcus Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.01 / 8.75Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat